Navigation Links
FDA Clears Abbott's i-STAT® 1 Wireless Point of Care Testing System
Date:3/29/2011

PRINCETON, N.J., March 29, 2011 /PRNewswire/ -- Abbott announced today it has received clearance from the U.S. Food and Drug Administration to begin marketing the i-STAT® 1 Wireless handheld, a new wireless version of the i-STAT® point of care testing system that is widely used in hospitals, emergency rooms and physicians' offices. The new i-STAT 1 Wireless handheld will allow real time transmission of diagnostic test results generated by i-STAT 1 directly from the patient bedside.

"With i-STAT 1 Wireless, caregivers are able to share critical test information electronically without leaving the patient's bedside," said Greg Arnsdorff, head of Abbott's point of care business. "By empowering nurses to stay at the bedside, the new i-STAT 1 Wireless supports a patient-focused approach to treatment, allowing for expedited decision making that helps minimize time to treatment."

The handheld analyzer can potentially save precious time by allowing caregivers to perform critical tests at the bedside and then transmit test results immediately so they can be reviewed by physicians anywhere they have access to electronic records.  Eliminating back-and-forth movement from the bedside to a desktop transmission terminal somewhere in the department gives staff the ability to better focus on the patient.

"With wireless, physicians can receive immediate test information in the electronic medical record, enabling them to act quickly when a patient's clinical status is rapidly changing," Arnsdorff said.

With the 10-minute i-STAT cardiac troponin test cartridge, for example, emergency department staffs can test, transmit and treat from the bedside. This helps health care providers maintain compliance with testing guidelines from the American College of Cardiology and American Heart Association, which call for a turnaround time of less than 60 minutes. By sharing these test results via a hospital's existing wireless network, caregivers have rapid access to information that can help determine if a patient is having a heart attack.

The i-STAT 1 Wireless handheld is certified for compatibility with existing wireless networks. It is also is compatible with point-of-care data management systems used with earlier versions of the i-STAT System.  The i-STAT 1 Wireless is the latest innovation from Abbott Point of Care, the U.S. market leader in bedside testing. The company offers the largest menu of diagnostic tests in a handheld platform and is used in nearly 2,000 hospitals in the U.S. and nearly 1,000 emergency departments.

About the i-STAT System

i-STAT 1 Wireless is a fully integrated system with a comprehensive test menu that enhances bedside testing workflow.  The i-STAT System can aide the physician in accelerating patient care decision making by quickly providing patient results that can be acted upon. Weighing just 18 ounces, the intuitive analyzer needs only two or three drops of blood to provide lab quality results.  Blood is added to disposable cartridges that contain test reagents; the cartridge is then inserted in the analyzer; and results are provided in minutes. In addition to cardiac markers, other i-STAT tests include chemistries, blood gases, electrolytes, and tests for lactate, hemoglobin, coagulation, and hematology.  In the U.S., the i-STAT System is used in nearly 2,000 hospitals and in nearly 1,000 emergency departments. Some 50,000 i-STAT analyzers are used worldwide and process about 100 million test cartridges a year. The system is relied on by clinicians in emergency departments, intensive care units, operating rooms, catheterization labs, outpatient clinics and physician offices. Technical support is available 24 hours a day. To learn more, visit www.abbottpointofcare.com.

About Abbott Point of Care

Abbott Point of Care, headquartered in Princeton, N.J., develops, manufactures and markets critical medical diagnostic and data management products for rapid blood analysis. The company's premier product is the i-STAT, a market-leading handheld blood analyzer capable of performing a panel of commonly ordered blood tests on two or three drops of blood at the patient's side.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's website at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears Palatin Technologies IND Filing to Commence Clinical Studies for Asthma
2. FDA Clears Test to Help Patients With Kidney Transplants
3. FDA Clears First Diagnostic Radiology Application for Mobile Devices
4. FDA Clears GeNO LLCs Investigational New Drug Application for Clinical Trials With Its NITROSYL™ Inhaled Nitric Oxide System
5. FDA Clears Volpara™ Breast Imaging Software for Automatic Calculation of Volumetric Breast Density
6. FDA Clears Cymbalta to Treat Chronic Musculoskeletal Pain
7. FDA Clears Software Upgrade for Fenwal Plasma-Collection System
8. FDA Clears AirStrip RPM for CRITICAL CARE & CARDIOLOGY Remote Patient Monitoring Solutions
9. FDA Clears Xlumenas NAVIX(TM) Access Device
10. FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni
11. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016  Landauer, Inc. (NYSE: LDR ... measurement and monitoring, outsourced medical physics services and high ... its fiscal 2016 first quarter ended December 31, 2015. ... Fiscal 2016 First Quarter Highlights , Revenue of ... quarter of 2015 , Domestic Radiation Measurement services revenues ...
(Date:2/9/2016)... , February 9, 2016 ... QIA) gab heute den Abschluss eines Kooperationsvertrags ... Förderung umfassender Lösungen in den Bereichen Next-Generation-Sequencing ... QGEN ; Frankfurt Prime Standard: QIA) ... 10x Genomics für die Entwicklung und Förderung ...
(Date:2/9/2016)... Feb. 9, 2016 Mast Therapeutics, Inc. ... for sickle cell disease and heart failure, today announced that ... to purchase common stock in an underwritten public offering.  The ... can be no assurance as to whether or when the ... or terms of the offering.   --> ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... ... The Journal of Pain Research has published the commentary “ Terminology of ... Dr John F. Peppin says “Terminology matters, yet little attention has been paid to ... cancer pain’ and ‘chronic non-cancer pain’ are replete in the literature; however, the distinction ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... The guide will ensure lab personnel have a basic understanding of the techniques ... measurement protocols. Enhanced understanding will help them reduce waste and rework to create ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... cleaning and sealing company , is proud to announce that many of their ... levels of customer service. The hard surface restoration franchises received customer recognition through ...
(Date:2/8/2016)... PLAINSBORO, N.J. (PRWEB) , ... February 08, 2016 , ... ... on cancer patients, has officially launched the Multiple Myeloma Heroes Awards event , ... (MM) or in the lives of patients with MM. The MM Heroes Awards ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie ... celebrates the beginning of a new charity campaign. As part of their ongoing ... Advocates (CASA). In the belief that children deserve a voice, and in the ...
Breaking Medicine News(10 mins):